IPCA Laboratories Limited vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of IPCA Laboratories Limited (IPCALAB) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads IPCALAB vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability13
  • Growth20
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

42.42
P/E ratio
71.32
6.20
P/B ratio
22.29
0.30%
Dividend yield
0.77%
₹44.98
EPS
₹63.92

Profitability

TORNTPHARM takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

14.15%
Return on equity
25.78%
18.49%
Return on capital
13.91%
20.51%
EBITDA margin
32.61%
12.27%
Net margin
15.29%

Growth

IPCALAB takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

15.60%
Revenue CAGR (3Y)
13.27%
35.20%
Profit CAGR (3Y)
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹46,494 Cr
Market cap
₹1.73L Cr
₹9,646 Cr
Revenue
₹13,980 Cr
₹1,184 Cr
Net profit
₹2,138 Cr
0.10
Debt / equity
1.79
IPCA Laboratories Limited
  • + []
  • − ["Stock is trading at 5.77 times its book value", "The company has delivered a poor profit growth of 0.7% over past five years."]
TORRENT PHARMACEUTICALS L
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 67.6%"]
  • − ["Stock is trading at 20.67 times its book value", "Company has a high debt to equity ratio of 1.79."]
IPCA Laboratories Limited full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.